Abstract:BACKGROUND:Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary tumor syndrome with an incidence of approximately 1/36,000. VHL disease-associated clear cell renal cell carcinoma (ccRCC) is the most common congenital RCC. Although recent advances in treating RCC have improved the long-term prognosis of patients with VHL disease, kidney cancer is still the leading cause of death in these patients. Therefore, finding new targets for diagnosing and treating VHL disease-associated ccRCC is still essential.METHODS:In this study, we collected matched tumor tissues and normal samples from 25 patients with VHL disease-associated ccRCC, diagnosed and surgically treated in the Department of Urology, Peking University First Hospital. After screening, we performed whole genome bisulfite sequencing (WGBS) on 23 pairs of tissues and RNA-seq on 6 pairs of tissues. And we also compared the VHL disease-associated ccRCC transcriptome data with the sporadic ccRCC transcriptome data from the The Cancer Genome Atlas (TCGA) public database RESULTS: We found that the methylation level of VHL disease-associated ccRCC tumor tissues was significantly lower than that of normal tissues. The tumor tissues showed a difference in the copy number of 3p loss and 5q and 7q gain compared with normal tissues. We integrated RNA-seq and WGBS data to reveal methylation candidate genes associated with VHL disease-associated ccRCC; our results showed 124 hypermethylated and downregulated genes, and 245 hypomethylated and upregulated genes. By comparing the VHL disease-associated ccRCC transcriptome data with the sporadic ccRCC transcriptome data from the TCGA public database, we found that the major pathways of differential gene enrichment differed between them.CONCLUSIONS:Our study mapped the multiomics of copy number variation, methylation and mRNA level changes in tumor and normal tissues of clear cell renal cell carcinoma with VHL syndrome, which provides a solid foundation for the mechanistic study, biomarker screening, and therapeutic target discovery of clear cell renal cell carcinoma.

[Somatic Mutations of VHL Gene and HIF-1alpha Expression in Primary Renal Clear Cell Carcinomas].

[The Expression of Hypoxia Inducible Factor-1,2 Alpha in Sporadic Clear Cell Renal Cell Carcinoma and Their Relationships to the Mutations of Von Hippel-Lindau Gene].

[Frequent Somatic Mutations of the Von Hippel-Lindau (VHL) Tumor Suppressor Gene and Its Meaning in Sporadic Human Renal Clear Cell Carcinoma].

[Frequent Somatic Mutations of the Von Hippel-Lindau Tumor Suppressor Gene in Primary Sporadic Human Renal Clear Cell Carcinomas].

Expression of the Hypoxia-Inducible Factors in the AML and MDS: is Not Associated with the Von Hippel-Lindau Gene

[Mutation of Von Hippel-Lindau Gene and Expression of Vascular Endothelial Growth Factor in Sporadic Clear Cell Renal Cell Carcinoma and Their Relationships to Angiogenesis].

A Clinical Analysis of Multilocular Cystic Renal Cell Carcinoma and Its Correlation with Mutation of the Von Hippel-Lindau Gene

[Expression of Hypoxia-Inducible Factor-1-alpha, Hypoxia-Inducible Factor-2Alpha and Vascular Endothelial Growth Factor in Sporadic Clear Cell Renal Cell Renal Cell Carcinoma and Their Significance in the Pathogenesis Thereof].

VHL Ser65 Mutations Enhance HIF2α Signaling and Promote Epithelial-Mesenchymal Transition of Renal Cancer Cells

Expression and significance of HIF-1α and HIF-2α in human renal clear cell cancer

Expression and significance of HIF-1α mRNA and HIF-2α mRNA in human renal clear cell cancer

[Analysis of Biallelic Inactivation of the Von Hippel-Lindau Tumor Suppressor Gene VHL in Patients of Renal Cell Carcinoma Patient].

Relationship between von Hipple-Lindau tumor suppressor gene mutations and the prognosis of Chinese sporadic clear cell renal cell carcinoma

The Relationship of Erythropoietin Overexpression with Von Hippel-Lindau Tumour Suppressor Gene Mutations Between Hypoxia-Inducible Factor-1Α and -2Α in Sporadic Clear Cell Renal Carcinoma

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic response

VHLmissense Mutation Delineate Aggressive Clear Cell Renal Cell Carcinoma Subtype with Favorable Immunotherapeutic Response

Clinical Significance of HIF-1α mRNA and HIF-2α mRNA Expression in Human Renal Clear Cell Cancer

VHL gene expression and its prognostic value in clear cell renal cell carcinoma

363: Somatic Mutations of the Von Hippel-Lindau (VHL) Tumor Suppressor Gene, Expression of Hypoxia Inducible Factor-α and Vascula Endothelial Growth Factor in Chinese Sporadic Clear Cell Renal Cell Carcinomas and Their Relationships to Angiogenesis

Correlation of ki 67 overexpression to mutations of von Hippel-Lindau gene in clear-cell renal cell carcinoma

Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated Ccrcc.